- Home
- WWR vs PRLD Comparison
WWR vs PRLD Comparison
Compare WWR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- PRLD
- Stock Information
- Founded
- WWR 1977
- PRLD 2016
- Country
- WWR United States
- PRLD United States
- Employees
- WWR N/A
- PRLD N/A
- Industry
- WWR Metal Mining
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- WWR Basic Materials
- PRLD Health Care
- Exchange
- WWR Nasdaq
- PRLD Nasdaq
- Market Cap
- WWR 48.0M
- PRLD 44.0M
- IPO Year
- WWR N/A
- PRLD 2020
- Fundamental
- Price
- WWR $0.72
- PRLD $1.25
- Analyst Decision
- WWR Strong Buy
- PRLD Strong Buy
- Analyst Count
- WWR 2
- PRLD 3
- Target Price
- WWR $2.00
- PRLD $4.00
- AVG Volume (30 Days)
- WWR 1.2M
- PRLD 219.0K
- Earning Date
- WWR 08-07-2025
- PRLD 11-05-2025
- Dividend Yield
- WWR N/A
- PRLD N/A
- EPS Growth
- WWR N/A
- PRLD N/A
- EPS
- WWR N/A
- PRLD N/A
- Revenue
- WWR N/A
- PRLD $7,000,000.00
- Revenue This Year
- WWR N/A
- PRLD N/A
- Revenue Next Year
- WWR N/A
- PRLD N/A
- P/E Ratio
- WWR N/A
- PRLD N/A
- Revenue Growth
- WWR N/A
- PRLD N/A
- 52 Week Low
- WWR $0.45
- PRLD $0.61
- 52 Week High
- WWR $1.32
- PRLD $5.53
- Technical
- Relative Strength Index (RSI)
- WWR 44.99
- PRLD 60.92
- Support Level
- WWR $0.65
- PRLD $1.10
- Resistance Level
- WWR $0.82
- PRLD $1.26
- Average True Range (ATR)
- WWR 0.05
- PRLD 0.15
- MACD
- WWR -0.01
- PRLD 0.00
- Stochastic Oscillator
- WWR 21.82
- PRLD 81.13
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.